The investigators of this study sought to assess whether short-term glucose control affects FEV1 recovery during acute pulmonary exacerbation in patients with cystic fibrosis-related diabetes.
Final height was impaired in boys with cystic fibrosis who experienced a rapid increase in body mass index between the ages of 1 and 6.
The FDA has expanded the indication for Kalydeco to include treatment of cystic fibrosis in patients 6 months of age and older.
Faster progression to end-stage lung disease observed in patients with cytomegalovirus immunoglobulin G positivity.
Approximately 70% azithromycin users with cystic fibrosis returned to ≥90% of baseline FEV1 compared with 61% of azithromycin nonusers.
Unselective small-molecule ion channels can restore host defenses in the airway epithelia of patients with cystic fibrosis.
Treating hemoptysis with antifibrinolytic therapy involving an inpatient and outpatient approach reduced hospital admissions in patients with cystic fibrosis.
Systemic antifibrinolytic therapy in adult patients with cystic fibrosis has been associated with a reduced rate of hospital admissions for hemoptysis.
Improvements in pancreatic function biomarkers, including increases in fecal elastase-1 and decreases in serum immunoreactive trypsinogen, were seen in patients treated with lumacaftor and ivacaftor.
Inhaled liposomal ciprofloxacin is associated with a longer median time to first pulmonary exacerbation vs placebo in patients with non-cystic fibrosis bronchiectasis and chronic P aeruginosa lung infection requiring antibiotic therapy.
